The Short Form-36: Pre- Versus Post-Surgical Administration in Cardiac Surgery Patients
This trial is active, not recruiting.
|Conditions||coronary artery bypass grafting, heart diseases, heart valve diseases|
|Sponsor||Weill Medical College of Cornell University|
|Start date||January 2000|
|End date||September 2007|
|Trial size||200 participants|
|Trial identifier||NCT00226265, 1203-069|
The purpose of this study is to determine whether the SF-36 can be administered reliably to cardiac surgery patients (two to three days) post-surgery, with the patient answering the questions of this survey from a pre-surgical perspective.
Male or female participants at least 18 years old.
- Cardiac surgery patients who are between the ages of 18 and 100
- Are English speaking
- Able to give consent
- Undergoing cardiac surgery including (but not limited to):
- Aortic valve replacement (AVR)
- Mitral valve replacement (MVR)
- Tricuspid valve replacement (TVR)
- Coronary artery bypass graft (CABG).
- Non-cardiac surgery patients
|Official title||The Short Form-36: Pre-vs. Post-Surgical Administration in Cardiac Surgery Patients|
|Principal investigator||Mary E Charlson, MD|
|Description||The purpose of this study, is to determine whether the SF-36 can be administered reliably to cardiac surgery patients (two to three days) post-surgery, with the patient answering the questions of this survey from a pre-surgical perspective.|
Call for more information